Last reviewed · How we verify
Fluorometholone 0.1% ophthalmic solution
Fluorometholone is a topical corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.
Fluorometholone is a topical corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammatory and allergic conditions of the eye including conjunctivitis, keratitis, and iritis, Post-operative inflammation following ocular surgery, Corneal injury and inflammation.
At a glance
| Generic name | Fluorometholone 0.1% ophthalmic solution |
|---|---|
| Sponsor | University of Pennsylvania |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Fluorometholone reduces inflammation by inhibiting the production of inflammatory mediators and suppressing immune cell activity in ocular tissues. It decreases vasodilation, edema, and cellular infiltration characteristic of inflammatory eye conditions. The drug is applied topically to the eye where it exerts local anti-inflammatory effects with minimal systemic absorption.
Approved indications
- Inflammatory and allergic conditions of the eye including conjunctivitis, keratitis, and iritis
- Post-operative inflammation following ocular surgery
- Corneal injury and inflammation
Common side effects
- Elevated intraocular pressure
- Cataract formation (with prolonged use)
- Local irritation or stinging
- Blurred vision
- Secondary ocular infection
Key clinical trials
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease (PHASE4)
- Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT (PHASE4)
- Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis (PHASE4)
- Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients (PHASE4)
- Topical Insulin Versus Autologous Serum After Corneal Surgeries (PHASE1)
- Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye (NA)
- The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |